How the rise of PTAB discretionary denials impacts Hatch-Waxman strategies
The recent rejection of a Mylan IPR petition – currently being challenged at the Federal Circuit – is good news for pharma patentees and bad news for generics
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.